Key result
This paper reviews the current evidence on left atrial appendage closure devices for cardiovascular risk reduction in patients with atrial fibrillation.
Why the study?
Do left atrial appendage closure devices reduce cardiovascular risk in patients with atrial fibrillation?
Do left atrial appendage closure devices reduce cardiovascular risk in patients with atrial fibrillation?
This review examines the current evidence for percutaneous left atrial appendage closure as an alternative to oral anticoagulants for thromboembolic prevention in atrial fibrillation.
LAA closure evidence in AF remains inconclusive; leaves open need for definitive RCTs before practice change.
Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice. AF is associated with a 4–5-fold increased risk of stroke and systemic embolism. Oral anticoagulant is the first-line therapy for this purpose, but it has various limitations and is often contraindicated or underutilized. Autopsy and surgical data have suggested that 90% of atrial thrombi in nonvalvular AF patients originate from the left atrial appendage, leading to the development of percutaneous closure for thromboembolic prevention. This paper examines the current evidence on left atrial appendage closure devices for cardiovascular risk reduction in AF patients.
No takes yet. Share an insight, caveat, or question.
Cruz‐González et al. (2015) conducted a review in Atrial fibrillation. Left atrial appendage closure devices was evaluated. This paper reviews the current evidence on left atrial appendage closure devices for cardiovascular risk reduction in patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: